← All trials
NCT03472508
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2018
- Primary completion
- Mar 30, 2019
- Completion date
- Jun 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 3600
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shenzhen Ausa Pharmed Co.,LtdLead sponsor
- Peking UniversityCollaborator
- Nanchang UniversityOverall official - principal investigator
- Nanchang UniversityCollaborator
- Southern Medical UniversityCollaborator
- The First People's Hospital of LianyungangCollaborator
- Anhui Medical UniversityCollaborator
- People's Hospital of RongchengCollaborator
- Shenzhen Evergreen Medical InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.